NCT02557035 · OUTCOME

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting · Source last updated 2018-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: >24-120 hours

Groups in this outcome

I.V. Palonosetron Infusion Plus Dexamethasone

Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

I.V. Palonosetron Bolus Plus Dexamethasone

Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
I.V. Palonosetron Infusion Plus Dexamethasone	225
I.V. Palonosetron Bolus Plus Dexamethasone	215

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
I.V. Palonosetron Infusion Plus Dexamethasone	170	Not reported	Not reported	Not reported	Not reported
I.V. Palonosetron Bolus Plus Dexamethasone	165	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
170
group Id
OG001
value
165

denoms

counts
group Id
OG000
value
225
group Id
OG001
value
215
units
Participants

groups

description
Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone
id
OG000
title
I.V. Palonosetron Infusion Plus Dexamethasone
description
Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone
id
OG001
title
I.V. Palonosetron Bolus Plus Dexamethasone

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

>24-120 hours

title

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice